| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13K | — | +49.2% |
| Cost of Revenue | $4K | — | +78.3% |
| Gross Profit | $6K | — | +332.8% |
| SG&A Expense | $4K | — | +12.0% |
| Operating Income | -$7K | — | +62.8% |
| Net Income | -$8K | — | +58.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Inventory | $17K | -18.9% | -76.0% |
| Current Assets | $22K | +2.8% | -68.9% |
| Total Assets | $22K | +2.8% | -68.9% |
| Current Liabilities | $195K | +4.5% | -23.1% |
| Total Liabilities | $278K | +3.1% | +9.7% |
| Stockholders' Equity |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $5K | — | +154.5% |
| Investing Cash Flow | $7K | — | +0.0% |
| Financing Cash Flow | -$438 | — | +0.0% |
Business Overview
Hi-Great Group Holding Company is a development stage enterprise focused on an exclusive global licensing agreement for KRAS gene research related to cancer treatment, while continuing to market and distribute SellaCare, Inc.'s organic longevity health supplements under a worldwide exclusive license agreement. The company is also diversifying into the cosmetic sector as part of its sustainable revenue strategy. During the three months ended March 31, 2026, the company generated $13,255 in sales, up from $8,883 in the prior year period, and reduced its net loss to $7,830 compared to $18,938 in the prior year.
Segment Performance
The company operates primarily in two areas: herbal supplements distribution and development-stage KRAS gene research. For the three months ended March 31, 2026, sales increased to $13,255 from $8,883 in the prior year period. Cost of sales decreased to $7,274 from $7,501 in the prior year, resulting in gross profit of $5,981 compared to $1,382. Operating expenses decreased from $20,758 to $13,186, primarily due to lower depreciation expense and professional fees. The company generated operating cash flow of $4,570 compared to cash used of $8,387 in the prior year period.
Forward Guidance
Management states it "believes that it will be successful in its capital formation and planned operating activities," but explicitly notes "there can be no assurance that the Company will be able to raise additional equity capital or be successful in the development and commercialization of the products it develops or initiates collaboration agreements thereon." The company indicates it is "making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect." No specific financial guidance, targets, or outlook metrics are provided.
Key Risk Factors
The company faces significant going concern risks as it has not established sufficient ongoing revenue to cover operating costs and remains dependent on debt and equity financing. The company has an accumulated deficit of $987,832 and stockholders deficit of $255,766, indicating substantial negative equity. Additionally, the company depends heavily on related party transactions, including a 25% royalty payment to SellaCare, Inc. (controlled by the majority shareholder) on all gross revenues, and is vulnerable to the impact of COVID-19 on business development and potential business combinations. The company's ability to successfully commercialize its KRAS gene-related products and maintain its licensing agreements is uncertain.
| -$256K |
| -3.2% |
| -40.4% |